— Know what they know.
Not Investment Advice

ENVB NASDAQ

Enveric Biosciences, Inc.
1W: -1.3% 1M: +2.8% 3M: +0.0% YTD: -59.7% 1Y: -81.4% 3Y: -99.6% 5Y: -100.0%
$1.48
+0.02 (+1.37%)
 
Weekly Expected Move ±6.4%
$1 $1 $1 $2 $2
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 49 · $6.6M mcap · 4M float · 3.09% daily turnover · Short 26% of daily vol

Balance Sheet Trends

Total Assets
$5M +65.3% ▲
5Y CAGR: +4.5%
Total Liabilities
$918K -38.4% ▼
5Y CAGR: +6.2%
Shareholders Equity
$4M +162.3% ▲
5Y CAGR: +4.1%
Cash & Investments
$5M +108.7% ▲
5Y CAGR: +24.3%
Total Debt
$0 +0.0% ▲
Net Debt
-$5M -108.7% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$17M$18M$2M$2M$5M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$17M$18M$2M$2M$5M
Net Receivables$0$0$225K$0$0
Inventory$0$0$0$0$0
Other Current Assets-$0$160K$568K$0$43K
Total Current Assets$18M$18M$4M$3M$5M
Property, Plant & Equip.$471K$741K$507K$306K$159K
Goodwill & Intangibles$9M$380K$211K$42K$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets-$0-$0$0$0$0
Total Non-Current Assets$9M$1M$718K$348K$159K
Total Assets$27M$20M$4M$3M$5M
— Liabilities —
Accounts Payable$683K$463K$1M$522K$581K
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$2M$351K$3K$252K
Total Current Liabilities$2M$4M$2M$1M$918K
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$2M-$0$0$0$0
Total Non-Current Liabilities$2M-$0$0$0$0
Total Liabilities$4M$4M$2M$1M$918K
— Equity —
Common Stock$7K$21K$27K$7K$11K
Retained Earnings-$61M-$79M-$96M-$106M-$115M
Accumulated OCI-$31K-$537K-$570K-$595K-$580K
Total Stockholders Equity$22M$15M$2M$2M$4M
Total Liabilities & Equity$27M$20M$4M$3M$5M
— Key Metrics —
Total Debt$176K$64K$0$0$0
Net Debt-$17M-$18M-$2M-$2M-$5M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms